Activation of peroxisome proliferator-activated receptor δ inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein
Abstract
Objective Hypertriglyceridemia is an important risk factor for cardiovascular disease. Elevated plasma very low-density lipoprotein (VLDL) puts insulin-resistant patients at risk for atherosclerosis. VLDL readily induces macrophage lipid accumulation and inflammatory responses, for which targeted therapeutic strategies remain elusive. We examined the ability of VLDL to induce macrophage foam cells and the inflammatory response and sought to define the cell signaling cascades involved. We further examined the potential of peroxisome proliferator-activated receptor (PPAR) δ activation to attenuate both VLDL-stimulated lipid accumulation and cytokine expression. Methods and results THP-1 macrophages exposed to VLDL displayed significant triglyceride accumulation, which was attenuated by PPARδ activation. PPARδ agonists stimulated a transcriptional program resulting in inhibition of lipoprotein lipase activity, activation of fatty acid uptake, and enhanced β-oxidation. VLDL-treated macrophages significantly increased the expression of activator protein 1 associated cytokines interleukin-1β, macrophage inflammatory protein 1α, and intercellular adhesion molecule-1. VLDL treatment significantly increased the phosphorylation of both extracellular signal-related kinase 1 and 2 and p38. VLDL reduced AKT phosphorylation as well as its downstream effector forkhead box protein O1, concomitant with increased nuclear forkhead box protein O1. Cells treated with PPARδ agonists were completel…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pretreatment with PPARd agonists attenuates VLDL-induced triglyceride accumulation by indirect inhibition of lipoprotein lipase.
“Interestingly, pretreatment with PPARd agonists attenuates VLDL-induced triglyceride accumulation by indirect inhibition of lipoprotein lipase (Bojic et al., 2012).”
PPARd selectively responds to different stimuli of lipid metabolism; VLDL reliably activates PPARd, whereas HDL and LDL do not.
“Furthermore, PPARd selectively responds to different”
These mechanisms result in lower triglyceride accumulation in cells treated with PPARd agonists than in THP-1 cells faced with VLDL alone.
“Collectively, these mechanisms result in lower triglyceride accumulation in cells treated with PPARd agonists than the THP-1 cells that are faced with VLDL alone (Bojic et al., 2012).”
The citation lists haven’t been fetched yet
References 48 · Cited by 51
- Authors
- Bojic, L. A., Sawyez, C. G., Telford, D. E., Edwards, J. Y., Hegele, R. A., & Huff, M. W.
- Affiliations
- Western University (CA)
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2012-12
- Volume
- 32
- Issue
- 12
- Pages
- 2919-2928
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2128469803
- Cited by
- 51
- References
- 48
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 6 · 2015: 5 · 2014: 5 · 2013: 10 · 2012: 1
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (FRN-8014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- PPARδ, VLDL, macrophage foam cell formation, macrophage inflammation, lipid accumulation, atherosclerosis, hypertriglyceridemia, lipoprotein lipase, fatty acid uptake, fatty acid beta-oxidation, MAPK signaling, ERK1/2, p38 MAPK, Akt signaling, FOXO1, IL-1β, macrophage inflammatory protein-1alpha, ICAM-1, PPARδ agonist, THP-1 macrophages
- MeSH terms
- Cell Differentiation, Cells, Cultured, Fatty Acids, Foam Cells, Humans, Inflammation, Ligands, Lipoproteins, VLDL, Macrophages, Triglycerides, Signal Transduction, Cytokines, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, PPAR delta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review